medigraphic.com
ISSN 2007-6053 (Print)
Órgano oficial de difusión de los Hospitales Regionales de Alta Especialidad (HRAE)

2011, Number 3

<< Back Next >>

Evid Med Invest Salud 2011; 4 (3)

Evaluation of functionality of the hand in children with spastic cerebral paralysis after one year of the administration of botulinum toxin type A and occupational therapy program

González-Serrano B, Mendoza-Medellín LN, Hamdan-Esquivel T

Language: Spanish
References: 31
Page: 96-103
PDF size: 174.97 Kb.


ABSTRACT

Introduction: Brain injury is an alteration of movement and posture, causing activity limitation. An alternative treatment is the use of Botulinum Toxin A, accompanied by a therapeutic program. The objective of study to evaluate the persistence of manual function and muscle tone, one year after the application of botulinum toxin A in children with spastic cerebral lesion.
Material and methods: A prospective, longitudinal study, with a sample size of 21 patients underwent an evaluation at one year after the application of botulinum toxin A.
Results: A one-year follow-up of the sample of 21 patients compared the results of the last full evaluation. It was observed that 57% of patients presented with apprehension-delayed grip, while 33% were able to grip normally, and only 10% continued to have abnormal gripping. Statistic analysis of the data shows that patients maintained an improved handgrip (p = .000). 48% of patients maintained a 1 + muscle tone and 24% were found with grade 2 muscle tone. A satisfaction survey reported that 47.6% of patient families found modest improvement in patient function.
Discussion: One year after the application of botulinum toxin A, the manual function of children persists if the treatment program is continued.


REFERENCES

  1. Datos estadísticos 2000-2008. Sistema Nacional para el Desarrollo Integral de la Familia, Dirección General de Rehabilitación y Asistencia Social/ Departamento de Epidemiología.

  2. Reddihough DS, Collins KJ. The epidemiology and causes of cerebral palsy. Australian Journal Physiotherapy 2003; 49: 7-12.

  3. Gad MB, Givon U. Cerebral Palsy: classification and etiology. Acta Orthop Traumatol Turc 2009; 43 (2): 77 – 80.

  4. Cans C, De la Cruz J, Mermet MA. Epidemi ology of cerebral palsy. Pediatrics and Child Health 2008; 18: 393-8.

  5. Desloovere K, MOlenares G, De Cat J, Pauwels P, Campenhout AV , Orbitus E et al. Motor function following multilevel botulinum toxin type A treatment in children with cerebral palsy. Developmental Medicine and Child Neurology 2007; 49 (1): 56-61.

  6. P óo P, Galvan MM, Casartelli MJ, López J, Gassio RM, Blanco C, Terricabras L. Toxina Botulínica en Parálisis Cerebral Infantil. Revista Neurológica 2008; 47 (Supl 1): S21-S24.

  7. Alejandro Ojeda Manzano, toxina botulínica como tratamiento de la espasticidad en la parálisis cerebral infantil. Rev Biomed 2004; 15: 107-112.

  8. Naidu K, Smith K, Shhedy M, Adair B, Yu X, Graham HK. Systemic adverse events following botulinum toxin A therapy children with cerebral palsy. Developmental Medicine and Child Neurology 2010; 52 (2): 139-144.

  9. Ward A. Sapaticity Treatment with botulinum toxins. Journal Neural Transm 2008; 115: 607-616.

  10. Stevenson V.L. Rehabilitation in practice: Spasticity management. Clinical Rehabilitation 2010; 24 (4): 293- 304.

  11. Cabañas F, Pellicer A. Lesión Cerebral en el niño prematuro. Rev Bi omed 2004; 15: 107- 112.

  12. Coutiño L.B. Daño neurológico encefálico por encefalopatía no progresiva. Última ed. Aguascalientes, México: Talleres de Servim presos del Centro S. A. De C. V; Octubre 2002.

  13. Juárez S.G. Toxina botulínica: uso en medicina de rehabilitación, mitos y realidades 2004; 16: 37-40.

  14. Turner A., Foster M., Johnson S.E. Terapia Ocupacional y disfunción física. 5ª ed. España. Elsevier, 2003.

  15. Trombly C.A. Terapia Ocupacional para enfermos incapacitados físicamente. La Prensa Médica Mexicana 1990; 173- 221.

  16. Hopkins HL, Smith H D. Terapia Ocupacional. 8ª. Edición España. Médica Panamericana 2001; 431-450.

  17. Díaz ML, Arellano SM, del Valle CM, Miranda DA , Rodríguez RG , Montero AA. Utilidad de la estim ulación eléctrica neuromuscular posterior a la aplicación de toxina botulínica en niños con hemi paresia espástica. Rev Mex Med Física y Rehabilitación 2005; 17: 16-22.

  18. Maya CM, Del Valle MG, Morales MG, Arellano ME. Utilidad de la toxina botulínica en la mejoría de la mano espástica en pacientes pediátricos con parálisis cerebral. Rev Mex Med Física y Rehabilitación 2004; 16: 18-22.

  19. Robaina CG , Rodríguez RS, Robaina M. Evaluación diagnóstica del niño con parálisis cerebral. Rev Cubana de Pediatría 2007; 79: 147-149.

  20. Forssberg H, Tedroff KB. Botulinum toxin treatment in cerebral palsy. Dev Med Child Neurol 1997; 39: 635-640.

  21. Bustamante J. Neuroanatomía Funcional. Fondo Educativo Interamericano 1978; 45: 70-83.

  22. Young PA . Neuroanatomía Clínica Funcional. Masson. España 2001; 35-40.

  23. Royal College of Physicians, British Society of Rehabilitation Medicine, Chartered Society of Physiotherapy, Association of Chartered Physiotherapists Interested in Neurology. Spasticity in adults: management using botulinum toxin. National Guidelines. London: RCP ; 2009.

  24. Simpson DM, Gracies JM, Graham HK, Miyasaki JM, Naumann M, Russman B, Simpson LL, So Y. Assessment: Botulinum neurotoxin for the treatment of spasticity (an evidence-based review): report of the Therapeutics and Technology Assessment Subcommi ttee of the American Academy of Neurology. Neurology 2008; 70 (19): 1691-8.

  25. Corry IS, Cosgrove AP, Walsh EG, Mc- Clean D, Graham HK. Botulinum toxin A in the hemiplegic upper lim b: a doubleblind trial. Dev Med Child Neurol 1997; 39: 185-193.

  26. Fehlings D, Rang M, Glazier J, Steele C. An evaluation of botulinum-A toxin injections to im prove upper extremi ty function in children wi th hemi plegic cerebral palsy. J Pediatr 2000; 137: 331- 337.

  27. S peth LA, Leffers P, Janssen-Potten YJ, Vles JS. Botulinum toxin A and upper limb functional skills in hemiparetic cerebral palsy: a randomized trial in children receiving intensive therapy. Dev Med Child Neurol 2005 ;47: 468-473.

  28. Vivancos-Matellano F, Pascual-Pascual SI, Nardi-Vilardaga J, Miquel-Rodríguez F, De Miguel-León I, Martínez- Garre MC, et al. Guía del tratamiento integral de la espasticidad. Rev Neurol 2007; 45: 365-75.

  29. Young R, Delwai de P. Drug therapy, spasticity. N Engl J Med 1981; 304: 28- 33.

  30. Brin MF. Spasticity: etiology, evaluation, management, and the role of botulinum toxin type A. Muscle Nerve 1997; 20 (Suppl 6): S146-68.

  31. Garces K, McCormi ck A, McGahan L, Ski dmore B. Botulinum toxin A in the treatment of upper and lower lim b spasticity: a systematic review of randomized controlled trials. Ottawa: Canadian Coordinating Office for Health Technology Assessment (CCOHTA ); 2006.




2020     |     www.medigraphic.com